Evaluation of Corneal Histopathologic Changes  in Rabbits Due to Topical Mitomycin C  Application in Different Doses and Periods

Kemal Yar; Altan A. Ozcan; Yurdun Kuyucu; Seyda Erdoğan; Sait Polat

doi:10.5152/eurjther.2019.18045

Authors

Kemal Yar Department of Surgical Medicine, Çukurova University School of Medicine, Adana, Turkey https://orcid.org/0000-0002-6822-8584
Altan A. Ozcan Department of Surgical Medicine, Çukurova University School of Medicine, Adana, Turkey https://orcid.org/0000-0002-5563-8234
Yurdun Kuyucu Department of Surgical Medicine, Çukurova University School of Medicine, Adana, Turkey https://orcid.org/0000-0001-6289-0860
Seyda Erdoğan Department of Surgical Medicine, Çukurova University School of Medicine, Adana, Turkey https://orcid.org/0000-0001-7729-7664
Sait Polat Department of Surgical Medicine, Çukurova University School of Medicine, Adana, Turkey https://orcid.org/0000-0003-1646-8831

DOI:

https://doi.org/10.5152/eurjther.2019.18045

Keywords:

Cornea, topical mitomycin C, toxic effect

Abstract

Purpose: To evaluate the histopathological changes in the cornea owing to topical mitomycin C (MMC) application in various doses and administration periods.
Methods: The study group consisted of 35 albino rabbits with a mean age of 6 months. The animals were divided into the 7 groups, with each group comprising 10 eyes of 5 rabbits. Five rabbits were used as the control group, and the others were divided into groups according to the application period. The first 3 groups subsequently underwent 0.2, 0.4, and 0.8 mg/mL mitomycin C application 6 times at weekly intervals. Groups 4, 5, and 6 underwent MMC application at the same doses 12 times. The control group underwent topical physiological serum application. After the last treatment, the rabbits were sacrificed and enucleation was performed.
Results: Light and electron microscopic examinations of MMC-treated animals revealed different histopathological changes in the corneal epithelium and endothelium, according to various doses and administration periods.
Conclusion: Topical MMC has toxic effects on the cornea related to dose and period, and it is known to be more toxic in increased doses. In this study, we identified the most effective dose without side effects. Long-term treatment with MMC at low doses is more advantageous than short-term treatment at high doses.

Metrics

Metrics Loading ...

References

Abraham LM, Selva D, Casson R, Leibovitch I. Mitomycin Clinical Applications in Ophthalmic Practice. Drugs 2006; 66: 321-40.

Nanji AA, Sayyad FE, Karp CL. Topical chemotherapy for ocular surface squamous neoplasia. Curr Opin Ophthalmol 2013; 24: 336-42.

Mohan RR, Hutcheon AE, Choi R, Hong J, Lee J, Mohan RR, et al. Apoptosis, necrosis, proliferation, and myofibroblast generation in the stroma following LASIK and PRK. Exp Eye Res 2003; 76: 71-87.

Gharaee H, Zarei-Ghanavati S, Alizadeh R, Abrishami M. Endothelial cell changes after photorefractive keratectomy with graded usage of mitomycin C. Int Ophthalmol 2018; 38: 1211-7.

Zare M, Jafarinasab MR, Feizi S, Zamani M. The effect of mitomycin-C on corneal endothelial cells after photorefractive keratectomy. J Ophthalmic Vis Res 2011; 6: 8-12.

Shojaei A, Ramezanzadeh M, Soleyman-Jahi S, Almasi Nasrabadi M, Rezazadeh P, Eslani M. Short-time mitomycin-C application during photorefractive keratectomy in patients with low myopia. J Cataract Refract Surg 2013; 39: 197-203.

Khong JJ, Muecke J. Complications of mitomycin ctherapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol 2006; 90: 819-22.

Avisar R, Apel I, Avisar I, Weinberger D. Endothelial cell loss during piterygium surgery: importance of timing of mitomycin capplication. Cornea 2009; 28: 879-81.

Song JS, Kim JH, Yang M, Sul D, Kim HM. Concentrations of mitomycin cin rabbit corneal tissue and aqueous humor after topical application. Cornea 2006; 25: S20-3.

Chang SW. Early corneal edema following topical applicationof mitomycin c.J Cataract Refract Surg 2004; 30: 1742-50.

Poothullil AM, Colby KA. Topical Medical Therapies for Ocular Surface Tumors Semin Ophthalmol 2006; 21: 161-9.

Prabhasawat P, Tarinvorakup P, Tesavibul N, Uiprasertkul M, Kosrirukvongs P, Booranapong W, et al. Topical 0.002% mitomycin cfor the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma. Cornea 2005; 24: 443-8.